No Data
No Data
No Data
No Data
No Data
Some Investors May Be Willing To Look Past Hubei Hongyuan Pharmaceutical Technology's (SZSE:301246) Soft Earnings
The market was pleased with the recent earnings report from Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246), despite the profit numbers being soft. However, we think the company is s
Simply Wall StApr 29 02:06 ET
Hongyuan Pharmaceutical (301246.SZ): Net profit of 31.991 million yuan in the first quarter decreased by 51.81% year-on-year
Gelonghui, April 22 | Hongyuan Pharmaceutical (301246.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 426 million yuan, down 15.45% year on year; net profit attributable to shareholders of listed companies was 31.991 million yuan, down 51.81% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 19.06.38 million yuan, down 62.26% year on year; basic earnings per share were 0.0780 yuan.
Gelonghui FinanceApr 22 08:58 ET
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) May Have Run Too Fast Too Soon With Recent 29% Price Plummet
Unfortunately for some shareholders, the Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) share price has dived 29% in the last thirty days, prolonging recent pain. The recent drop
Simply Wall StApr 15 19:23 ET
Hongyuan Pharmaceutical (301246.SZ): Initial repurchase of 110,000 shares involving 1.960.99 million yuan
Gelonghui, April 8, 丨 Hongyuan Pharmaceutical (301246.SZ) announced that on April 3, 2024, the company repurchased shares through centralized bidding transactions for the first time through a special stock repurchase securities account. The number of shares repurchased was 110,000 shares, accounting for 0.0275% of the company's current total share capital. The highest transaction price for the repurchase was 17.92 yuan/share, the minimum transaction price was 17.79 yuan/share, and the total transaction amount was 19.09.85 million yuan (excluding transaction fees).
Gelonghui FinanceApr 8 04:25 ET
Hongyuan Pharmaceutical (301246.SZ): Currently, the lithium battery materials industry is experiencing phased overcapacity
Gelonghui, April 8 | Hongyuan Pharmaceutical (301246.SZ) said on the investor interactive platform that the lithium battery materials industry is currently experiencing phased overcapacity, but the lithium battery industry will maintain a relatively rapid growth rate in the long run. In the future, the company will continue to enhance the competitiveness of the company's lithium hexafluorophosphate business through technological iterative upgrading and expansion upstream of the industrial chain. At the same time, it will lay out products such as additives and functional lithium salts, form industrial collaboration with the lithium hexafluorophosphate business, and continue to enhance the business scale and market competitiveness of the company's lithium battery sector. The company strictly complies with regulatory requirements and laws and regulations to fulfill its information disclosure obligations, and the company will pass
Gelonghui FinanceApr 8 03:09 ET
Hongyuan Pharmaceutical (301246.SZ): Repurchase has not been implemented
Gelonghui, April 2, 丨 Hongyuan Pharmaceutical (301246.SZ) announced that as of March 31, 2024, the company's special securities account had not implemented operations related to this share repurchase.
Gelonghui FinanceApr 2 04:30 ET
No Data
No Data